BALANCING DIVERSION CONTROL AND MEDICAL NECESSITY: THE CASE OF PRESCRIPTION DRUGS WITH ABUSE POTENTIAL

REFERENCES

• Batten H. L., Prottas J. M., Horgan C. M., et al. Drug Services Research Survey. Phase II Final Report. Institute for Health Policy, Brandeis University, Waltham, MA, Submitted to the National Institute on Drug Abuse. February 12, 1993
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA), National Household Survey on Drug Abuse: Main Findings 1991. DHHS Pub. No. (SMA)93 – 1980. Substance Abuse and Mental Health Services Administration. U.S. Department of Health and Human Services, May 1993
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA), National Household Survey on Drug Abuse: Population Estimates 1995. Substances Abuse and Mental Health Services Administration. U.S. Department of Health and Human Services, June 1996
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA), National, Household Survey on Drug Abuse: Main Findings 1994. DHHS Pub. No. (SMA)963085. Substance Abuse and Mental Health Services Administration. U.S. Department of Health and Human Services, September, 1996
   Google Scholar
• United States Department of Justice, Prescription Accountability Resource Guide. Drug Enforcement Administration, Office of Diversion Control, September, 1998
   Google Scholar
• Phelps J. R., Bormel F. G. NCSA Resolutions and an Update on Prescription Monitoring Programs. Pharmaceutical Distribution and Marketing Audits Update 1996; 3(4)24
   Google Scholar
• Gitchel G. T. Existing methods to identify retail drug diversion. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care, J. R. Cooper, D. J. Czechowicz, S. P. Molinari, R. C. Petersen. NIDA Monograph No. 131, NIH Pub. No. 93–3507.U.S., Department of Health and Human Services, Public Health Service, National Institutes of Health. 1993; 132–140
   Google Scholar
• Joranson D. E., Cleeland C. S., Weissman D. E., Gilson A. M. Opioids for Chronic Cancer and Non-cancer Pain – a Survey of State Medical Board Members. Fed. Bull. June 1992; 15–49
   Google Scholar
• Weissman M., Johnson J. Drug use and abuse in five U.S. communities. Presented at the Triplicate Prescription: Issues and Answers. Conference sponsored by the Medical Society of the State of New York, New York City, February, 281991
   Google Scholar
• Cleeland C. S. Pain control: public and physicians' attitudes. Advances in Pain Research and Therapy, C. S. Hill, Jr., W. S. Fields. Raven Press, Ltd, New York 1989; 11: 81–89
   Google Scholar
• Portenoy R. K. Chronic Opioid Therapy in Nonmalignant Pain. J. Pain Symptom Management 1990; 5(1; Suppl.)S46–S62
   PubMedGoogle Scholar
• Portenoy R. K., Dole V., Joseph H., Lowinson J,. et al. Pain Management and Chemical Dependency: Evolving Perspectives. JAMA 1997; 278: 592–593
   PubMedGoogle Scholar
• Breibart W., Rosenfeld B. D., Passik S. D., McDonald M. V., Portenoy R. K. The Undertreatment of Pain in Ambulatory AIDS Patients. Pain 1996; 65: 243–249
   PubMed Web of Science ®Google Scholar
• Sigler K. A., Guernsey B. G., Ingrim N. B., Buesing A. A. Effect of a Triplicate Prescription Law on the Prescribing of Schedule II Drugs. Am. J. Hosp. Pharm. 1984; 41: 108–111
   PubMedGoogle Scholar
• New York State Department of Health, New York State's Regulation Placing Benzodiazepines on Triplicate Prescription: The First Year 1989. New York State Department of Health, Division of Public Health Protection, May 25, 1990
   Google Scholar
• New York State Department of Health. Benzodiazepine Prescribing Declines Under Triplicate Program. Epidemiology Notes 1989; 4(12)
   Google Scholar
• Weintraub M., Singh S., Byrne L., Maharaj K., Guttmacher L. Consequences of the 1989 New York State Benzodiazepine Prescription Regulations. JAMA 1991; 266(17)2392–2397
   PubMedGoogle Scholar
• McNutt L. A., Coles F. B., McAuliffe T., Baird S., Morse D. L. et al. Impact of Regulation on Benzodiazepine Prescribing to a Low Income Elderly Population, New York State. J. Clin. Epidemiol. 1994; 47(6)613–625
   PubMed Web of Science ®Google Scholar
• Wastila L. J., Bishop C. The Influence of Multiple Copy Prescription Programs on Analgesic Utilization. J. Pharm. Care Pain Symptom Control 1996; 4(3)3–19
   Google Scholar
• Horgan C. H., Prottas J., Tompkins C., Wastila L., Bowden M. Summary and conclusions of a review of prescription drug diversion control methods. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care, J. R. Cooper, D. J. Czechowicz, S. P. Molinari, R. C. Petersen. NIDA Monograph No. 131, NIH Pub. No. 93–3507, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. 1993; 206–222
   Google Scholar
• Horgan C. H., Prottas J., Tompkins C., Wastila L., Bowden M. A. research agenda for prescription drug diversion control. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care, J. R. Cooper, D. J. Czechowicz, S. P. Molinari, R. C. Peterson. NIDA Monograph No. 131, NIH Pub. No. 93–3507, U.S. Department of Health and Human Services, Public Health Service, National Institute of Health. 1993; 309–324
   Google Scholar
• Carrow G., Horn D. Electronic data transfer – dispensing trends and enforcement activity. A Joint Publication of the Massachusetts Department of Public Health and the Bureau of Registration in Pharmacy, 1–3, Pharmacy Update. Winter, 1995–19961(2)
   Google Scholar
• Additional Effect of the Triplicate Program, Epidemiology Notes. New York State Department of Health, 1990, 5(1)
   Google Scholar
• Drug Enforcement Administration, DEA Resource Guide. United States Department of Justice, May 1990
   Google Scholar
• Lewin/ICF. Analysis of Prescription Monitoring Programs. Prepared for Hoffiman-LaRoche by Lewin/ICF, Washington, DC, April, 261991
   Google Scholar
• American Psychiatric Association. Benzodiazepine Dependence, Toxicity and Abuse: a Task Force report of the American Psychiatric Association, C. Salzman. American Psychiatric, Press. May 1990
   Google Scholar
• Belizzi J. J. Triplicate prescriptions: issues and answers, law enforcement perspective. Presentation at Triplicate Prescription: Issues and Answers. Conference sponsored by the Medical Society of the State of New York, New York City, February, 281991
   Google Scholar
• Eadie J. L. New York state's triplicate prescription program. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient care, J. R. Cooper, D. J. Czechowicz, S. P. Molinari, R. C. Petersen. NIDA Research Monograph No. 131, NIH Pub. No. 93–3507, National Institutes of Health. U.S. Department of Health and Human Services. 1993; 176–193
   Google Scholar
• Wilford B. B. Legislative Digest. American Medical Association, Chicago, Illinois 1998
   Google Scholar
• Cancer Care. Improving Access to Pain Medications in New York: a Proposal for Discussion and Action. 1995, Cancer Care: New York
   Google Scholar
• Berina L. F., Guernsey B. G., Hokanson J. A., Doutre W. K., Fuller L. E. Physician perceptions of a Triplicate Prescription Law. Am. J. Hosp. Pharm. 1984; 42: 857–9
   Google Scholar
• Dodd E. OSTAR – Oklahoma schedule II abuse reduction: an electronic point of sale diversion control system. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care, J. R. Cooper, D. J. Czechowicz, S. P. Molinari, R. C. Petersen. NIDA Research Monograph No. 131, NIH Pub. No. 93–3507, National Institutes of Health. U.S. Department of Health and Human Services. 1993; 151–158
   Google Scholar
• Simoni-Wastila L., Tompkins C., Carrow G., Bhalotra S., Physician Knowledge of and Attitudes Toward Prescription Drug Monitoring in Massachusetts. Study in progress
   Google Scholar
• Collins T. Cost issues: multiple copy prescription programs and alternative monitoring programs. Presentation at Triplicate Prescription, Issues and Answers. Conference sponsored by the Medical Society of the State of New York, New York City, February, 281991
   Google Scholar
• Bishop M. T., Vlasty R. J. The Illinois experience in achieving the medical/regulatory balance required to control prescription drug diversion. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care, J. R. Cooper, D. J. Czechowicz, S. P. Molinari, R. C. Petersen. NIDA Research Monograph No. 131, NIH Pub. No. 93–3507, National Institutes of Health. U.S. Department of Health and Human Services. 1993; 159–175
   Google Scholar
• Bormel G. EDT advisory a success. A Joint Publication of the Massachusetts Department of Public Health and the Bureau of Registration in Pharmacy. Pharmacy Update. Summer 1995; 1(1)1–2
   Google Scholar
• Maddaloni M. A., Hoffman R. S., Wipfler W. G., et al. The Effect of the Triplicate Benzodiazepine Prescription regulation on sedative-hypnotic overdoses. Veterinary and Human Toxicology August 1990; 32(4)355
   Google Scholar
• Oklahoma State Bureau of Narcotics and Dangerous Drugs Control: OSTAR Update. Oklahoma City, Oklahoma: Bureau of Narcotics, 1994
   Google Scholar
• Haislip G. R. Drug diversion control systems, medical practice, and patient care. Impact of prescription Drug Diversion Control Systems on Medical Practice and Patient Care, J. R. Cooper, D. J. Czechowicz, S. P. Molinari, R. C. Petersen. NIDA Monograph No. 131, NIH Pub. No. 93–3507, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health. 1993; 120–130
   Google Scholar
• Zullich S. G., Grasela T. H., Fiedler-Kelly J. B., Genzo F. M. Impact of Triplicate Prescription Program on Psychotropic Prescribing in Long-term Care Facilities. Ann. Pharmacother 1992; 26: 539–546
   PubMedGoogle Scholar
• Wastila L. J., The Influence of Multiple Copy Prescription Programs on Analgesic Utilization. Dissertation Published 1993. UMI Dissertation Services, Ann Arbor, MI
   Google Scholar
• Kozma C. M., Reeder C. E., Lingle E. W. Expanding Medicaid Drug Formulary Coverage: Effects on Utilization of Related Services. Medical Care 1990; 28(10)963–966
   PubMed Web of Science ®Google Scholar
• Lingle E. W., Reeder C. E., Kozma C. A. Impact of an Open Formulary System on the Utilization of Medical Services. J. Res. Pharm. Econ. 1990, Spring
   Google Scholar
• Soumerai S. B., Ross-Degnan D., Avorn J., McLaughlin T. J. 1Choodnovsky 1. Effects of Medicaid Drug-payment Limits on Admission to Hospitals and Nursing Homes. N. Engl. J. Med. 1991; 325(15)1072–1077
   PubMed Web of Science ®Google Scholar
• Soumerai S. B., McLaughlin T. J., Ross-Degnan D., Casteris C., Bollini P. Effects of Limiting Medicaid Drug-reimbursement Benefits on the use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia. N. Engl. J. Med. 1994; 331: 650–655
   PubMed Web of Science ®Google Scholar